Why Vaxcyte, Inc.’s (PCVX) Stock Is Up 5.32%
As of Friday, October 09, Vaxcyte, Inc.’s PCVX share price has surged by 5.32%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Commentary & Analysis
Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 9.91%
As of Tuesday, October 06, Vaxcyte, Inc.’s PCVX share price has dipped by 9.91%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vaxcyte, Inc.’s (PCVX) Stock Is Down 10.55%
As of Tuesday, October 06, Vaxcyte, Inc.’s PCVX share price has dipped by 10.55%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vaxcyte, Inc.’s (PCVX) Stock Is Up 52.27%
As of Monday, October 05, Vaxcyte, Inc.’s PCVX share price has surged by 52.27%, which has investors questioning if this is right time to sell.Michael Rose
Why Vaxcyte, Inc.’s (PCVX) Stock Is Up 32.08%
As of Monday, October 05, Vaxcyte, Inc.’s PCVX share price has surged by 32.08%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,621.7 | $242.6 | 79% |
|
| Shares Out (Mil) | 144.5 | 54.0 | 70% |
|
| Institutional Ownership | 99.4% | 93.1% | 88% |
|
| Float (Mil) | 136.4 | 41.4 | 67% |
|
| Beta | 1.21 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 5,329 | 633 | 92% |
|
| Price Change (52-week) |
75.2% | 50.0% | 91% |
|
| Growth | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (53.8%) | (10.1%) | 6% |
|
| EPS (5yr) | (13.3%) | 15.8% | 20 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($2.136) | ($8.233) | ($7.194) | |
| Month Ago EPS | ($2.139) | ($8.197) | ($7.217) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($2.164) | ($8.483) | ($7.421) | |
| Year/Year Chg | 8.5% | 46.2% | 8.3% | |
| Financials | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($1,064) | ($44) | 1% |
|
| EPS (TTM) | ($7.647) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($881) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($123) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $109 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $7,947 | $177 | 70% |
|
| Valuation | PCVX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.75 | 2.33 | 73% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (33.0%) | (47.6%) | 16% |
|
| ROE | (36.5%) | (54.9%) | 18% |
|
| Liabilities to Assets | 12.1% | 29.3% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Vaxcyte, Inc. did not pass any screens on 10/9/2026.
